MK-4074 200 mg + Placebo for MK-4074 + Pioglitazone hydrochloride 30 mg + Placebo for pioglitazone hydrochloride
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-alcoholic Fatty Liver Disease
Conditions
Non-alcoholic Fatty Liver Disease
Trial Timeline
Oct 26, 2011 → Oct 1, 2012
NCT ID
NCT01431521About MK-4074 200 mg + Placebo for MK-4074 + Pioglitazone hydrochloride 30 mg + Placebo for pioglitazone hydrochloride
MK-4074 200 mg + Placebo for MK-4074 + Pioglitazone hydrochloride 30 mg + Placebo for pioglitazone hydrochloride is a phase 1 stage product being developed by Merck for Non-alcoholic Fatty Liver Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01431521. Target conditions include Non-alcoholic Fatty Liver Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01431521 | Phase 1 | Completed |
Competing Products
20 competing products in Non-alcoholic Fatty Liver Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IVA337 + IVA337 + Placebo | Inventiva | Phase 2 | 47 |
| GODEX + Placebo | Celltrion | Phase 3 | 77 |
| ASP9831 + Placebo | Astellas Pharma | Phase 2 | 52 |
| AZD9550 + AZD9550 + Placebo | AstraZeneca | Phase 1 | 33 |
| AZD2693 | AstraZeneca | Phase 1 | 33 |
| placebo + Omega-3 carboxylic acids + Dapagliflozin + Placebo | AstraZeneca | Phase 2 | 52 |
| AZD4831 | AstraZeneca | Phase 2 | 52 |
| AZ compound | AstraZeneca | Phase 2 | 52 |
| cotadutide solution for injection | AstraZeneca | Phase 1 | 33 |
| Cotadutide + Cotadutide-placebo + Moxifloxacin + Moxifloxacin-placebo | AstraZeneca | Phase 1 | 33 |
| AZD4076 + Placebo | AstraZeneca | Phase 1 | 33 |
| Placebo + Omega-3 carboxylic acid + Fenofibrate 200mg + Placebo | AstraZeneca | Phase 2 | 52 |
| Cotadutide + Placebo | AstraZeneca | Phase 2 | 52 |
| AZD7503 Intervention | AstraZeneca | Phase 1 | 33 |
| Efinopegdutide + Semaglutide + Placebo | Merck | Phase 2 | 52 |
| Efinopegdutide | Merck | Phase 1 | 33 |
| LIK066 + Placebo | Novartis | Phase 2 | 52 |
| Tropifexor (LJN452) + Cenicriviroc (CVC) | Novartis | Phase 2 | 52 |
| LYS006 + Tropifexor | Novartis | Phase 2 | 52 |
| LMB763 + Placebo | Novartis | Phase 2 | 52 |